Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 03 May, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 539871 | NSE: THYROCARE

Thyrocare Technologies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 3, 2025, 9:00 pm

Market Cap 4,750 Cr.
Current Price 896
High / Low 1,055/571
Stock P/E49.6
Book Value 101
Dividend Yield2.01 %
ROCE27.6 %
ROE18.2 %
Face Value 10.0
PEG Ratio-10.02

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Thyrocare Technologies Ltd

Competitors of Thyrocare Technologies Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
NG Industries Ltd 53.0 Cr. 158 206/1454.37 1242.21 %6.50 %5.63 % 10.0
Global Longlife Hospital and Research Ltd 24.3 Cr. 23.2 46.4/18.3122 25.50.00 %0.98 %0.77 % 10.0
Gian Lifecare Ltd 17.2 Cr. 16.6 27.0/12.14.20 19.20.00 %29.2 %24.6 % 10.0
Fortis Malar Hospitals Ltd 143 Cr. 76.4 98.7/51.0186 15.955.6 %3.29 %9.12 % 10.0
Family Care Hospitals Ltd 25.6 Cr. 4.74 9.50/3.400.67 2.670.00 %15.4 %24.1 % 10.0
Industry Average24,117.43 Cr701.5960.7287.902.67%12.25%11.61%9.08

All Competitor Stocks of Thyrocare Technologies Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 110123119125117125124136123141144163153
Expenses 74868596911029010092108101114112
Operating Profit 36373430262333373134424940
OPM % 33%30%28%24%22%18%27%27%25%24%29%30%26%
Other Income 1211120223324
Interest 1111111111110
Depreciation 79889999111091015
Profit before tax 29292722181524282125354028
Tax % 22%31%24%35%28%33%31%28%28%23%28%27%32%
Net Profit 23202014131017201519253019
EPS in Rs 4.273.853.802.702.391.883.163.832.813.634.755.593.60

Last Updated: February 28, 2025, 4:35 pm

Below is a detailed analysis of the quarterly data for Thyrocare Technologies Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is 153.00 Cr.. The value appears to be declining and may need further review. It has decreased from 163.00 Cr. (Sep 2024) to 153.00 Cr., marking a decrease of 10.00 Cr..
  • For Expenses, as of Dec 2024, the value is 112.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 114.00 Cr. (Sep 2024) to 112.00 Cr., marking a decrease of 2.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Sep 2024) to 40.00 Cr., marking a decrease of 9.00 Cr..
  • For OPM %, as of Dec 2024, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 30.00% (Sep 2024) to 26.00%, marking a decrease of 4.00%.
  • For Other Income, as of Dec 2024, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2024) to 4.00 Cr., marking an increase of 2.00 Cr..
  • For Interest, as of Dec 2024, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
  • For Depreciation, as of Dec 2024, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Sep 2024) to 15.00 Cr., marking an increase of 5.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Sep 2024) to 28.00 Cr., marking a decrease of 12.00 Cr..
  • For Tax %, as of Dec 2024, the value is 32.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Sep 2024) to 32.00%, marking an increase of 5.00%.
  • For Net Profit, as of Dec 2024, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 30.00 Cr. (Sep 2024) to 19.00 Cr., marking a decrease of 11.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 3.60. The value appears to be declining and may need further review. It has decreased from 5.59 (Sep 2024) to 3.60, marking a decrease of 1.99.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:35 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 134150180235298332370401474562486524600
Expenses 7181109140182193222233304330371388435
Operating Profit 64697195115139148168171232115136165
OPM % 47%46%40%40%39%42%40%42%36%41%24%26%27%
Other Income 187136-162114-351275612
Interest 0001000113553
Depreciation 361111121214202128343945
Profit before tax 78697389871481471121612078198128
Tax % 27%33%33%34%46%35%35%29%26%27%30%28%
Net Profit 5746495947969579120152577193
EPS in Rs 52.0442.289.7510.948.6917.8718.0415.0122.6528.7410.7613.4317.57
Dividend Payout % 0%0%157%91%115%56%111%33%110%52%167%134%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-19.30%6.52%20.41%-20.34%104.26%-1.04%-16.84%51.90%26.67%-62.50%24.56%
Change in YoY Net Profit Growth (%)0.00%25.82%13.89%-40.75%124.59%-105.30%-15.80%68.74%-25.23%-89.17%87.06%

Thyrocare Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:10%
3 Years:4%
TTM:21%
Compounded Profit Growth
10 Years:7%
5 Years:-2%
3 Years:-14%
TTM:39%
Stock Price CAGR
10 Years:%
5 Years:13%
3 Years:6%
1 Year:42%
Return on Equity
10 Years:20%
5 Years:20%
3 Years:14%
Last Year:18%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 6:42 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 11115154545453535353535353
Reserves 149195229322364400403325393468468461426
Borrowings 25250000091021213917
Other Liabilities 11141439263132557355706884
Total Liabilities 197246293414444485488442528597612620581
Fixed Assets 7587839389103108112119149157159151
CWIP 10661201482111
Investments 77119162266299315289239274259274291236
Other Assets 3433425554688988127186180169193
Total Assets 197246293414444485488442528597612620581

Below is a detailed analysis of the balance sheet data for Thyrocare Technologies Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹53.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 53.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹426.00 Cr.. The value appears to be declining and may need further review. It has decreased from 461.00 Cr. (Mar 2024) to ₹426.00 Cr., marking a decrease of 35.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹17.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2024) to ₹17.00 Cr., marking a decrease of 22.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹84.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 68.00 Cr. (Mar 2024) to ₹84.00 Cr., marking an increase of 16.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹581.00 Cr.. The value appears to be improving (decreasing). It has decreased from 620.00 Cr. (Mar 2024) to ₹581.00 Cr., marking a decrease of 39.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹151.00 Cr.. The value appears to be declining and may need further review. It has decreased from 159.00 Cr. (Mar 2024) to ₹151.00 Cr., marking a decrease of 8.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹236.00 Cr.. The value appears to be declining and may need further review. It has decreased from 291.00 Cr. (Mar 2024) to ₹236.00 Cr., marking a decrease of 55.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹193.00 Cr.. The value appears strong and on an upward trend. It has increased from 169.00 Cr. (Mar 2024) to ₹193.00 Cr., marking an increase of 24.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹581.00 Cr.. The value appears to be declining and may need further review. It has decreased from 620.00 Cr. (Mar 2024) to ₹581.00 Cr., marking a decrease of 39.00 Cr..

Notably, the Reserves (426.00 Cr.) exceed the Borrowings (17.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +4636678911297136111106120155191
Cash from Investing Activity +-52-21-19-40-48-327-53-12-32-80-55
Cash from Financing Activity +0-23-45-48-65-96-163-58-87-88-84-124
Net Cash Flow-6-731-1-31061-912

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow39.0044.0071.0095.00115.00139.00148.00159.00161.00211.0094.0097.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days912911710111434606328
Inventory Days5454475464665460505463106
Days Payable21358423196248305283
Cash Conversion Cycle615351576853461237847451
Working Capital Days1922521528114-99493925
ROCE %50%33%27%27%29%33%31%36%37%41%15%18%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters71.18%71.18%71.18%71.14%71.14%71.14%71.14%71.14%71.11%71.11%71.11%71.11%
FIIs12.02%12.68%12.82%10.42%10.13%9.99%3.44%3.46%3.35%2.90%2.49%1.93%
DIIs6.71%6.88%7.15%9.14%8.68%8.45%13.46%13.33%13.89%14.88%14.89%14.80%
Public10.09%9.26%8.85%9.29%10.04%10.40%11.95%12.08%11.64%11.11%11.49%12.16%
No. of Shareholders65,76966,31566,43171,41275,82274,38676,29272,00068,84464,82361,63659,377

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund1,778,1650.24108.491,778,1652025-04-22 17:25:170%
Nippon India Pharma Fund1,765,8381.56107.741,765,8382025-04-22 15:19:420%
ICICI Prudential India Opportunities Fund1,184,1310.4572.251,184,1312025-04-22 17:25:170%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund765,0471.3146.68765,0472025-04-22 15:19:420%
Nippon India Retirement Fund - Wealth Creation Scheme321,9030.6719.64321,9032025-04-22 17:25:180%
ICICI Prudential Bharat Consumption Fund230,2810.6414.05230,2812025-04-22 17:25:180%
ICICI Prudential Retirement Fund - Pure Equity12,6310.140.7712,6312025-04-22 15:19:420%
ICICI Prudential Retirement Fund - Hybrid Aggressive1,1860.020.071,1862025-04-22 15:19:420%
Motilal Oswal S&P BSE Healthcare ETF1630.10.011632025-04-22 17:25:180%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 13.4212.1633.3021.4116.74
Diluted EPS (Rs.) 13.4012.1433.2521.3716.71
Cash EPS (Rs.) 21.9319.2539.7327.1422.67
Book Value[Excl.RevalReserv]/Share (Rs.) 99.65101.1299.5480.8169.39
Book Value[Incl.RevalReserv]/Share (Rs.) 99.65101.1299.5480.8169.39
Revenue From Operations / Share (Rs.) 108.0099.50111.3293.5582.18
PBDIT / Share (Rs.) 27.7224.2749.9334.7434.11
PBIT / Share (Rs.) 18.8516.9643.5329.0228.07
PBT / Share (Rs.) 18.0516.5143.0828.8526.48
Net Profit / Share (Rs.) 13.0511.9433.3321.4116.63
NP After MI And SOA / Share (Rs.) 13.3612.1633.3021.4016.73
PBDIT Margin (%) 25.6624.3944.8537.1341.50
PBIT Margin (%) 17.4417.0439.1031.0134.15
PBT Margin (%) 16.7116.5938.7030.8332.21
Net Profit Margin (%) 12.0811.9929.9422.8920.23
NP After MI And SOA Margin (%) 12.3712.2229.9122.8720.35
Return on Networth / Equity (%) 13.4312.0433.4526.4824.11
Return on Capital Employeed (%) 18.0316.1542.3934.0338.11
Return On Assets (%) 10.9810.1728.9820.7318.77
Long Term Debt / Equity (X) 0.020.000.000.000.01
Total Debt / Equity (X) 0.040.000.000.000.01
Asset Turnover Ratio (%) 0.890.790.980.940.87
Current Ratio (X) 3.083.544.182.501.86
Quick Ratio (X) 2.553.183.802.261.61
Inventory Turnover Ratio (X) 4.385.826.807.446.03
Dividend Payout Ratio (NP) (%) 134.63123.2945.0246.69149.32
Dividend Payout Ratio (CP) (%) 80.8976.9837.7636.84109.71
Earning Retention Ratio (%) -34.63-23.2954.9853.31-49.32
Cash Earning Retention Ratio (%) 19.1123.0262.2463.16-9.71
Interest Coverage Ratio (X) 34.9554.67111.45211.1497.43
Interest Coverage Ratio (Post Tax) (X) 17.4527.8975.40131.1452.06
Enterprise Value (Cr.) 3118.272246.854079.234758.172609.92
EV / Net Operating Revenue (X) 5.454.276.939.626.01
EV / EBITDA (X) 21.2417.4915.4425.9014.48
MarketCap / Net Operating Revenue (X) 5.484.326.959.656.03
Retention Ratios (%) -34.63-23.2954.9753.30-49.32
Price / BV (X) 5.954.267.7711.177.14
Price / Net Operating Revenue (X) 5.484.326.959.656.03
EarningsYield 0.020.020.040.020.03

After reviewing the key financial ratios for Thyrocare Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 13.42. This value is within the healthy range. It has increased from 12.16 (Mar 23) to 13.42, marking an increase of 1.26.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 13.40. This value is within the healthy range. It has increased from 12.14 (Mar 23) to 13.40, marking an increase of 1.26.
  • For Cash EPS (Rs.), as of Mar 24, the value is 21.93. This value is within the healthy range. It has increased from 19.25 (Mar 23) to 21.93, marking an increase of 2.68.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 99.65. It has decreased from 101.12 (Mar 23) to 99.65, marking a decrease of 1.47.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 99.65. It has decreased from 101.12 (Mar 23) to 99.65, marking a decrease of 1.47.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 108.00. It has increased from 99.50 (Mar 23) to 108.00, marking an increase of 8.50.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 27.72. This value is within the healthy range. It has increased from 24.27 (Mar 23) to 27.72, marking an increase of 3.45.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 18.85. This value is within the healthy range. It has increased from 16.96 (Mar 23) to 18.85, marking an increase of 1.89.
  • For PBT / Share (Rs.), as of Mar 24, the value is 18.05. This value is within the healthy range. It has increased from 16.51 (Mar 23) to 18.05, marking an increase of 1.54.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 13.05. This value is within the healthy range. It has increased from 11.94 (Mar 23) to 13.05, marking an increase of 1.11.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 13.36. This value is within the healthy range. It has increased from 12.16 (Mar 23) to 13.36, marking an increase of 1.20.
  • For PBDIT Margin (%), as of Mar 24, the value is 25.66. This value is within the healthy range. It has increased from 24.39 (Mar 23) to 25.66, marking an increase of 1.27.
  • For PBIT Margin (%), as of Mar 24, the value is 17.44. This value is within the healthy range. It has increased from 17.04 (Mar 23) to 17.44, marking an increase of 0.40.
  • For PBT Margin (%), as of Mar 24, the value is 16.71. This value is within the healthy range. It has increased from 16.59 (Mar 23) to 16.71, marking an increase of 0.12.
  • For Net Profit Margin (%), as of Mar 24, the value is 12.08. This value exceeds the healthy maximum of 10. It has increased from 11.99 (Mar 23) to 12.08, marking an increase of 0.09.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.37. This value is within the healthy range. It has increased from 12.22 (Mar 23) to 12.37, marking an increase of 0.15.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 13.43. This value is below the healthy minimum of 15. It has increased from 12.04 (Mar 23) to 13.43, marking an increase of 1.39.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 18.03. This value is within the healthy range. It has increased from 16.15 (Mar 23) to 18.03, marking an increase of 1.88.
  • For Return On Assets (%), as of Mar 24, the value is 10.98. This value is within the healthy range. It has increased from 10.17 (Mar 23) to 10.98, marking an increase of 0.81.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 23) to 0.02, marking an increase of 0.02.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.04. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.04, marking an increase of 0.04.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.89. It has increased from 0.79 (Mar 23) to 0.89, marking an increase of 0.10.
  • For Current Ratio (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has decreased from 3.54 (Mar 23) to 3.08, marking a decrease of 0.46.
  • For Quick Ratio (X), as of Mar 24, the value is 2.55. This value exceeds the healthy maximum of 2. It has decreased from 3.18 (Mar 23) to 2.55, marking a decrease of 0.63.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.38. This value is within the healthy range. It has decreased from 5.82 (Mar 23) to 4.38, marking a decrease of 1.44.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 134.63. This value exceeds the healthy maximum of 50. It has increased from 123.29 (Mar 23) to 134.63, marking an increase of 11.34.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 80.89. This value exceeds the healthy maximum of 50. It has increased from 76.98 (Mar 23) to 80.89, marking an increase of 3.91.
  • For Earning Retention Ratio (%), as of Mar 24, the value is -34.63. This value is below the healthy minimum of 40. It has decreased from -23.29 (Mar 23) to -34.63, marking a decrease of 11.34.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 19.11. This value is below the healthy minimum of 40. It has decreased from 23.02 (Mar 23) to 19.11, marking a decrease of 3.91.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 34.95. This value is within the healthy range. It has decreased from 54.67 (Mar 23) to 34.95, marking a decrease of 19.72.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 17.45. This value is within the healthy range. It has decreased from 27.89 (Mar 23) to 17.45, marking a decrease of 10.44.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 3,118.27. It has increased from 2,246.85 (Mar 23) to 3,118.27, marking an increase of 871.42.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.45. This value exceeds the healthy maximum of 3. It has increased from 4.27 (Mar 23) to 5.45, marking an increase of 1.18.
  • For EV / EBITDA (X), as of Mar 24, the value is 21.24. This value exceeds the healthy maximum of 15. It has increased from 17.49 (Mar 23) to 21.24, marking an increase of 3.75.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.32 (Mar 23) to 5.48, marking an increase of 1.16.
  • For Retention Ratios (%), as of Mar 24, the value is -34.63. This value is below the healthy minimum of 30. It has decreased from -23.29 (Mar 23) to -34.63, marking a decrease of 11.34.
  • For Price / BV (X), as of Mar 24, the value is 5.95. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 23) to 5.95, marking an increase of 1.69.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.32 (Mar 23) to 5.48, marking an increase of 1.16.
  • For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Thyrocare Technologies Ltd as of May 3, 2025 is: 744.06

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of May 3, 2025, Thyrocare Technologies Ltd is Overvalued by 16.96% compared to the current share price 896.00

Intrinsic Value of Thyrocare Technologies Ltd as of May 3, 2025 is: 707.21

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of May 3, 2025, Thyrocare Technologies Ltd is Overvalued by 21.07% compared to the current share price 896.00

Last 5 Year EPS CAGR: -4.95%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 31.42%, which is a positive sign.
  2. The stock has a low average Working Capital Days of 22.00, which is a positive sign.
  3. The company has higher reserves (354.08 cr) compared to borrowings (12.85 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (365.08 cr) and profit (113.69 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 53.92, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Thyrocare Technologies Ltd:
    1. Net Profit Margin: 12.08%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 18.03% (Industry Average ROCE: 12.25%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 13.43% (Industry Average ROE: 11.61%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 17.45
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.55
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 49.6 (Industry average Stock P/E: 60.72)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.04
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Thyrocare Technologies Ltd. is a Public Limited Listed company incorporated on 28/01/2000 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L85110MH2000PLC123882 and registration number is 123882. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 633.10 Cr. and Equity Capital is Rs. 52.99 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesD/37-1, TTC Industrial Area, New Mumbai Maharashtra 400703investor_relations@thyrocare.com
http://www.thyrocare.com
Management
NamePosition Held
Mr. Rahul GuhaManaging Director & CEO
Mr. Dharmil ShethNon Executive Director
Mr. Hardik DedhiaNon Executive Director
Mr. Dhaval ShahNon Executive Director
Mr. Gopalkrishna Shivram HegdeIndependent Director
Dr. Indumati GopinathanIndependent Director
Dr. Neetin S DesaiIndependent Director
Dr. Prapti GiladaIndependent Director
Dr. Harshil VoraIndependent Director
Mr. Nishant A ShahIndependent Director
Mr. Anandh SundarIndependent Director

FAQ

What is the intrinsic value of Thyrocare Technologies Ltd?

Thyrocare Technologies Ltd's intrinsic value (as of 03 May 2025) is ₹744.06 — 16.96% lower the current market price of 896.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,750 Cr. market cap, FY2025-2026 high/low of ₹1,055/571, reserves of 426 Cr, and liabilities of 581 Cr.

What is the Market Cap of Thyrocare Technologies Ltd?

The Market Cap of Thyrocare Technologies Ltd is 4,750 Cr..

What is the current Stock Price of Thyrocare Technologies Ltd as on 03 May 2025?

The current stock price of Thyrocare Technologies Ltd as on 03 May 2025 is 896.

What is the High / Low of Thyrocare Technologies Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Thyrocare Technologies Ltd stocks is ₹1,055/571.

What is the Stock P/E of Thyrocare Technologies Ltd?

The Stock P/E of Thyrocare Technologies Ltd is 49.6.

What is the Book Value of Thyrocare Technologies Ltd?

The Book Value of Thyrocare Technologies Ltd is 101.

What is the Dividend Yield of Thyrocare Technologies Ltd?

The Dividend Yield of Thyrocare Technologies Ltd is 2.01 %.

What is the ROCE of Thyrocare Technologies Ltd?

The ROCE of Thyrocare Technologies Ltd is 27.6 %.

What is the ROE of Thyrocare Technologies Ltd?

The ROE of Thyrocare Technologies Ltd is 18.2 %.

What is the Face Value of Thyrocare Technologies Ltd?

The Face Value of Thyrocare Technologies Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Thyrocare Technologies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE